FDA Approves Liquid Marijuana for AIDS and Cancer Patients

Photo Credit: High Times Magazine

Photo Credit: High Times Magazine

There is now a new treatment option available to AIDS and cancer patients now that the FDA has approved of a liquid synthetic version of the cannabinoid tetrahydrocannabidiol (THC). The liquid THC synthetic, which will be sold under the name Syndros, could help treat "anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.” This new form of synthetic THC can be swallowed easily and is designed to be quickly absorbed, which is considered an improvement from the other synthetic cannabinoids that already exist like dronabinol. 

This medication is easily accessible as a Schedule III substance, meaning it has low risk for abuse and has medicinal value. That being said, for those who can access medical marijuana, there are benefits to using the whole natural cannabis plant due to its varieties of cannabinoids and terpenes that work synergistically in what is known as the entourage effect. Even Dr. Sanjay Gupta has said of marinol vs. whole plant cannabis, "When the drug became available in the mid-1980s, scientists thought it would have the same effect as the whole cannabis plant. But it soon became clear that most patients preferred using the whole plant to taking Marinol... Researchers began to realize that other components, such as CBD, might have a larger role than previously realized.”

This information has been provided by High Times Magazine and approved by our Chief Medical Officer.